/R E P E A T -- Media Invite - Noise from REM in operation: Technical presentation/
MONTREAL, Sept. 22, 2023 /CNW/ - CDPQ Infra invites media representatives to a technical presentation to provide an update on the results of the analysis work carried out by acoustics experts on the operating section of the REM, as well as on the mitigation measures that will be deployed to address the current situation in the Griffintown, Pointe-Saint-Charles and L'Ile-des-Soeurs areas.
Jean-Marc Arbaud, President and CEO at CDPQ Infra, Philippe Batani, Senior Vice-President, Public Affairs, Communications and Strategy of CDPQ Infra and Elizabeth Boivin, Environment director of CDPQ Infra and Jean-Luc Wojtowicki, Acoustics & Vibration Project Manager, SYSTRA, will attend this update.
September 25, 2023
Time: 11:00 a.m.
Caisse de dépôt et placement du Québec
1000 Place Jean-Paul-Riopelle Montréal, Québec H2Z 2B3 (Room B1.01)
Sequence of events:
11 a.m. Press conference begins (In person and virtually - see below)
11 :35 a.m. Question period
12 :15 p.m. Press conference ends
The presentation will also be broadcast on the Digicast platform. To take part in this press conference, either in person or virtually, you need to register in advance using the contact details below, specifying your participation mode. A media kit containing a press release, the presentation and the report will be sent to media attending the conference.
Scenic Biotech, a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, today announced positive preclinical data for its lead small molecule QPCTL inhibitor, SC-2882. The data was also presented today by...
Blueprint Medicines Corporation today announced data showcasing its commitment to advance the scientific understanding and treatment of systemic mastocytosis (SM) at the 65th American Society of Hematology (ASH)...
Rallybio Corporation , a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today presented details from the Rallybio Fetal and...
Genmab A/S and AbbVie today announced new data from the ongoing phase 1/2 EPCOREtm NHL-1 clinical trial investigating epcoritamab (DuoBody® CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an overall...
bluebird bio, Inc. ("bluebird bio" or "bluebird") today announced new and updated efficacy, safety and health-related quality of life (HRQoL) data from the Phase 1/2 HGB-206 Group C and Phase 3 HGB-210 studies of lovotibeglogene autotemcel...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the primary analysis of the Phase III HAVEN 7 study reinforced the efficacy and safety of Hemlibra® (emicizumab-kxwh) in previously untreated or minimally...